Liraglutide is a new injectable anti-diabetic medicine. It can lower blood glucose and also result in aneutral or lowered body weight. However, the interaction of changes in blood glucose and body weight is not clear. This study is a retrospective chart review study. Patients with type 2 diabetes who initiated liraglutide therapy from 1, Sep. 2016 to 30 Nov. 2016 were enrolled. We assessed the change in blood glucose and body weight after liraglutide treatment. Results: The study found that most patients had lower A1C and body weight simultaneously but no relationship between body weight and blood glucose change was found. In multivariable linear regression models, variables such as male, diabetes duration, and baseline A1C are all positively correlated and numbers of anti-diabetic drugs is negatively correlated to the change of A1C. Age is positively correlated and the number of anti-diabetic drugs is negatively correlated to body weight change. We found that liraglutide could decrease body weight and blood glucose. However, there is no relationship between the glucose reduction and body weight lowering effects. In respect of glucose reduction, male patients with longer diabetes durations, using less oral anti-diabetic drugs or higher baseline A1C are good candidates for liraglutide treatment. In respect of body weight reduction, younger patients with more anti-diabetic drugs are less likely to lose their body weight. (J Intern Med Taiwan 2020; 31: 202-209)